Gaps in treatment amongst metastatic castration resistant prostate cancer (mCRPC) patients taking abiraterone acetate or enzalutamide.

被引：0
|
作者：
Behl, Ajay
Ellis, Lorie
Pilon, Dominic
Xiao, Yongling
Lefebvre, Patrick
Dawson, Nancy Ann
机构：
[1] Janssen Sci Affairs LLC, Horsham, PA USA
[2] 1000 Gauchetiere Ouest, Montreal, PQ, Canada
[3] Grp Anal Ltee, Montreal, PQ, Canada
[4] Lombardi Comprehens Canc Ctr, Washington, DC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 02期
关键词：
D O I：
10.1200/jco.2016.34.2_suppl.334
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
334
引用
收藏
页数：1
相关论文
共 50 条
  • [41] REAL-WORLD TREATMENT SEQUENCING OF ABIRATERONE AND ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC): WHAT ARE THE HEALTH ECONOMIC IMPLICATIONS?
    Pereira-Salgado, A.
    Tran, B.
    Kwan, E.
    Angelyn, A.
    Gibbs, P.
    IJzerman, M. J.
    VALUE IN HEALTH, 2019, 22 : S460 - S460
  • [42] Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression
    Becker, Daniel J.
    Iyengar, Arjun D.
    Punekar, Salman R.
    Ng, Jason
    Zaman, Anika
    Loeb, Stacy
    Becker, Kevin D.
    Makarov, Danil
    ANTICANCER RESEARCH, 2019, 39 (05) : 2467 - 2473
  • [43] PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival
    K. Rahbar
    M. Boegemann
    A. Yordanova
    M. Eveslage
    M. Schäfers
    M. Essler
    H. Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 12 - 19
  • [44] Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration -resistant prostate cancer (mCRPC).
    Parimi, Sunil
    Eigl, Bernhard J.
    Sunderland, Katherine
    Zulficiar, Muhammad
    Finch, Daygen L.
    Oja, Conrad D.
    Vergidis, Joanna
    Seto, Leanne Chung-Yon
    Azad, Arun
    Gleave, Martin
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [45] Abiraterone and enzalutamide in the first line therapy of metastatic castration resistant prostate cancer
    Al-Samsam, Sofya
    Bartos, Jiri
    Samal, Vladimir
    Dvorak, Josef
    Kolarova, Hana
    Richter, Igor
    REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2024, 29 (01) : 1 - 9
  • [46] Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer
    Giuseppe L. Banna
    Valeria Urzia
    Chiara Benanti
    Alessandra Pitrè
    Helga Lipari
    Rosario Di Quattro
    Ugo De Giorgi
    Giuseppe Schepisi
    Umberto Basso
    Davide Bimbatti
    Francesco Rundo
    Massimo Libra
    Lorenzo Malatino
    Supportive Care in Cancer, 2020, 28 : 4687 - 4695
  • [47] Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer
    Banna, Giuseppe L.
    Urzia, Valeria
    Benanti, Chiara
    Pitre, Alessandra
    Lipari, Helga
    Di Quattro, Rosario
    De Giorgi, Ugo
    Schepisi, Giuseppe
    Basso, Umberto
    Bimbatti, Davide
    Rundo, Francesco
    Libra, Massimo
    Malatino, Lorenzo
    SUPPORTIVE CARE IN CANCER, 2020, 28 (10) : 4687 - 4695
  • [48] Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
    Rana, Dikshyanta
    Geue, Claudia
    Baillie, Kelly
    Pan, Jiafeng
    Mueller, Tanja
    Laskey, Jennifer
    Bennie, Marion
    Clarke, Julie
    Jones, Robert J.
    Brown, Ailsa
    Wu, Olivia
    PHARMACOECONOMICS-OPEN, 2022, 6 (02) : 303 - 313
  • [49] Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
    Dikshyanta Rana
    Claudia Geue
    Kelly Baillie
    Jiafeng Pan
    Tanja Mueller
    Jennifer Laskey
    Marion Bennie
    Julie Clarke
    Robert J. Jones
    Ailsa Brown
    Olivia Wu
    PharmacoEconomics - Open, 2022, 6 : 303 - 313
  • [50] Response to Enzalutamide in patients with metastatic Castration-resistant prostate (mCRCP) cancer after chemotherapy and Abiraterone treatment
    Stroelin, P.
    Tennstedt, P.
    Steuber, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 87 - 87
12345